Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 401–500 of 1,002
Efficacy and safety of currently marketed anti-osteoporosis medications
Reginster, J., Neuprez, A., Dardenne, N., Beaudart, C., Emonts, P., & Bruyère, O. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.003 · Cited by 63
Self-citationDenosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis
Cummings, S. R., Martín, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P. D., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000363236.41902.96 · Cited by 63
Self-citationKUSHIDA, K., Fukunaga, M., Kishimoto, H., Shiraki, M., Itabashi, A., Inoue, T., Kaneda, K., Morii, H., Nawata, H., Yamamoto, K., et al. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0509-z · Cited by 62
Sebba, A. I., Bonnick, S. L., Kagan, R., Thompson, D. E., Skalky, C. S., Chen, E., & de Papp, A. E. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x16768 · Cited by 62
Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis
Songpatanasilp, T., Sritara, C., Kitisomprayoonkul, W., Chaiumnuay, S., Nimitphong, H., Charatcharoenwitthaya, N., Pongchaiyakul, C., Namwongphrom, S., Kitumnuaypong, T., Srikam, W., et al. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.10.002 · Cited by 61
Levis, S., Quandt, S. A., Thompson, D. E., Scott, J. C., Schneider, D. L., Ross, P. D., Black, D. M., Suryawanshi, S., Hochberg, M. C., & Yates, J. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50102.x · Cited by 61
Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?
Li, Z., Chines, A. A., & Meredith, M. P. (2004) · PubMed · Cited by 61
Bourrin, S., Ammann, P., Bonjour, J., & Rizzoli, R. (2002) · Bone · doi:10.1016/s8756-3282(01)00661-5 · Cited by 61
&NA; (2001) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200103000-00003 · Cited by 60
Utility of DXA for monitoring, technical aspects of DXA BMD measurement and precision testing
CAREY, J. J., & Delaney, M. F. (2017) · Bone · doi:10.1016/j.bone.2017.05.021 · Cited by 59
Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies
Reginster, J., & Meunier, P. J. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1349-0 · Cited by 59
Self-citationEfficacy and safety of alendronate and risedronate for postmenopausal osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x100276 · Cited by 59
Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence
Sampalis, J. S., Adachi, J. D., Rampakakis, E., Vaillancourt, J., Karellis, A., & Kindundu, C. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.533 · Cited by 58
Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club
Gielen, E., Bergmann, P., Bruyère, O., Cavalier, E., Delanaye, P., Goemaere, S., Kaufman, J., Locquet, M., Reginster, J., Rozenberg, S., et al. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0266-3 · Cited by 58
Self-citationRodrigues, A. M., Canhão, H. M., Marques, A., Ambrósio, C., Borges, J., Coelho, P. S., Costa, L. M. S. F., Fernandes, S., Gonçalves, I., Gonçalves, M., et al. (2018) · PubMed · Cited by 58
Kendler, D. L., Compston, J. E., CAREY, J. J., Wu, C., Ibrahim, A., & Lewiecki, E. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.07.010 · Cited by 58
Pazianas, M., Blumentals, W. A., & Miller, P. D. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0502-1 · Cited by 58
Boonen, S., Haentjens, P., Vandenput, L., & Vanderschueren, D. (2003) · Journal of Internal Medicine · doi:10.1046/j.0954-6820.2003.01258.x · Cited by 58
Risedronate: A Clinical Review
Crandall, C. J. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.353 · Cited by 58
Peripheral or Central Densitometry: Does It Matter Which Technique We Use?
Blake, G. M., & Fogelman, I. (2001) · Journal of Clinical Densitometry · doi:10.1385/jcd:4:2:083 · Cited by 58
Hara, K., Suda, T., Suda, J., Eguchi, M., Ihle, J. N., Nagata, S., Miura, Y., & Saito, M. (1988) · PubMed · Cited by 58
Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney, A., Adachi, J., Guyatt, G. H., Παπαϊωάννου, Α., Robinson, V., Shea, B., Tugwell, P., Waldegger, L., Weaver, B., Wells, G. A., et al. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523 · Cited by 58
Liu, G., Wang, Z., Liu, L., Zhang, B., Miao, Y., & Yu, S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26550 · Cited by 57
Jin, Y., Lee, J. H., Xu, B., & Cho, M. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2769-8 · Cited by 57
Differences between the bisphosphonates for the prevention and treatment of osteoporosis.
Grey, A. B., & Reid, I. R. (2006) · PubMed Central · Cited by 57
Camm, A. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.014 · Cited by 57
Vochteloo, A. J. H., van der Burg, B. L. S. B., Röling, M. A., van Leeuwen, D. H., van den Berg, P., Niggebrugge, A. H. P., de Vries, M. R., Tuinebreijer, W. E., Bloem, R. M., Nelissen, R. G. H. H., et al. (2012) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-012-1520-9 · Cited by 57
Canine Cancellous Bone Microarchitecture after One Year of High-Dose Bisphosphonates
Ding, M. L., Day, J. S., Burr, D. B., Mashiba, T., Hirano, T., Weinans, H., Sumner, D. R., & Hvid, I. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2066-6 · Cited by 57
Yang Li, C., Majeska, R. J., Laudier, D. M., Mann, R., & Schaffler, M. B. (2005) · Bone · doi:10.1016/j.bone.2005.04.041 · Cited by 56
Review of osteoporosis pharmacotherapy for geriatric patients
Gates, B. J., Sonnett, T. E., DuVall, C. A. K., & Dobbins, E. K. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.12.004 · Cited by 56
NOFSA Guideline for the Diagnosis and Management of Osteoporosis
Hough, S. F., Ascott-Evans, B. H., Brown, S. L., Cassim, B., de Villiers, T. J., Lipschitz, S., Pettifor, J. M., & Sonnendecker, E. W. W. (2010) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2010.10872239 · Cited by 56
Bisphosphonates in the treatment of osteoporosis
Poole, K. E. S., & Compston, J. E. (2012) · BMJ · doi:10.1136/bmj.e3211 · Cited by 56
Li, M., Law, S. W., Cheng, J. C. Y., Kee, H.-M., & Wong, M. S. (2014) · Prosthetics and Orthotics International · doi:10.1177/0309364614528204 · Cited by 56
Osteoporosis treatment: a missed opportunity
Milat, F., & Ebeling, P. R. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00568 · Cited by 56
Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis
Albert, S. G., & Reddy, S. (2017) · Endocrine Practice · doi:10.4158/ep161678.ra · Cited by 56
Anti-resorptives in the management of osteoporosis
Miller, P. D. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.004 · Cited by 56
Fleurence, R., Iglesias, C. P., & Torgerson, D. J. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1943-z · Cited by 56
Ito, M., Nishida, A., Aoyagi, K., Uetani, M., Hayashi, K., & Kawase, M. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1802-3 · Cited by 56
Schimmer, R. C., & Bauss, F. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90005-1 · Cited by 56
Medical treatment of vertebral osteoporosis
Lippuner, K. (2003) · European Spine Journal · doi:10.1007/s00586-003-0608-x · Cited by 56
Cooper, C. C., Reginster, J., Cortet, B., Díaz Curiel, M., Lorenc, R. S., Kanis, J. А., & Rizzoli, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.663750 · Cited by 55
Self-citationDecreased bone mineral density and periodontal management
Reddy, M. S., & Morgan, S. L. (2012) · Periodontology 2000 · doi:10.1111/j.1600-0757.2011.00400.x · Cited by 55
Zhang, L., Pang, Y., Shi, Y., Xu, M., Xu, X., Ju, Z., Ji, L., & Zhao, D. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000466 · Cited by 55
Tauchmanovà, L., Selleri, C., Esposito, M., Somma, C. D., Orio, F., Bifulco, G., Palomba, S., Lombardi, G., Rotoli, B., & Colao, A. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1520-2 · Cited by 55
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M., & Haentjens, P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02010.x · Cited by 55
Jansen, J. P., Bergman, G. J. D., Huels, J., & Olson, M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903035281 · Cited by 47
Hooper, M. J., Ebeling, P. R., Roberts, A. P., Graham, J. J., Nicholson, G. C., D'Emden, M., Ernst, T. F., & Wenderoth, D. (2005) · Climacteric · doi:10.1080/13697130500118126 · Cited by 54
Self-citationBrent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 54
Heckman, G. A., Παπαϊωάννου, Α., Sebaldt, R. J., Ioannidis, G., Petrie, A., Goldsmith, C. H., & Adachi, J. D. (2002) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-3-6 · Cited by 54
Drug Insight: existing and emerging therapies for osteoporosis
Mulder, J. E., Kolatkar, N. S., & LeBoff, M. S. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0325 · Cited by 54
Miller, P. D. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.04.005 · Cited by 54
Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
Eastell, R., Vittinghoff, E., Lui, L., Ewing, S. K., Schwartz, A. V., Bauer, D. C., Black, D. M., & Bouxsein, M. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4697 · Cited by 53
Self-citationCancer Treatment–Related Bone Loss: A Review and Synthesis of the Literature
Khan, M. N., & Khan, A. A. (2008) · Current Oncology · doi:10.3747/co.2008.174 · Cited by 53
Migliaccio, S., Brama, M., & Spera, G. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.55 · Cited by 53
Liberman, U. A., Hochberg, M. C., Geusens, P., SHAH, A., Lin, J. T., Chattopadhyay, A., & Ross, P. D. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01148.x · Cited by 53
Adverse drug reactions to osteoporosis treatments
Rizzoli, R., & Reginster, J. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.42 · Cited by 52
Self-citationThe cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®
Borgström, F., Ström, O., Coelho, J., Johansson, H., Odén, A., McCloskey, E. V., & Kanis, J. A. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0989-8 · Cited by 52
Malouf, J., Tarantino, U., García-Hernández, P. A., Corradini, C., Overgaard, S., Stepan, J. J., Borris, L. C., Lespessailles, É., Frihagen, F., Papavasiliou, K., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3067 · Cited by 52
Skeletal effects of zoledronic acid in an animal model of chronic kidney disease
Allen, M. R., Chen, N. X., Gattone, V. H., Chen, X., Carr, A., LeBlanc, P., Brown, D. M., & Moe, S. M. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2103-x · Cited by 52
Fukunaga, M., KUSHIDA, K., Kishimoto, H., Shiraki, M., Taketani, Y., MINAGUCHI, H., Inoue, T. M. N., Morita, R., Morii, H., Yamamoto, K., et al. (2002) · Osteoporosis International · doi:10.1007/s001980200135 · Cited by 52
Uncertain Future of Trials in Osteoporosis
Kanis, J. A., Odén, A., Johnell, O., Caulin, F., Bone, H. G., Alexandre, J. M., Abadie, E., & Lekkerkerker, F. J. F. (2002) · Osteoporosis International · doi:10.1007/s001980200052 · Cited by 52
on the behalf of the Study group, Esposti, L. D., Girardi, A. M., Saragoni, S., Sella, S., Andretta, M., Rossini, M., & Giannini, S. (2018) · Endocrine · doi:10.1007/s12020-018-1824-9 · Cited by 51
Medical treatment of osteoporosis
Palacios, S. (2021) · Climacteric · doi:10.1080/13697137.2021.1951697 · Cited by 51
Wilkes, M. M., Navickis, R. J., Chan, W. W., & Lewiecki, E. M. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0991-1 · Cited by 51
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
McClung, M. R., Balske, A., Burgio, D. E., Wenderoth, D., & Recker, R. R. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2175-7 · Cited by 47
Pazianas, M., Blumentals, W. A., & Miller, P. D. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0547-1 · Cited by 51
Ip, T., Cheung, S.-K. W., Cheung, T.-C., Choi, T.-C., Chow, S.-L. E., Ho, Y.-Y. A., Kan, S.-Y. A., Kung, W. C. A., Lee, K.-K., Leung, K. L. F., et al. (2013) · PubMed · Cited by 51
Tuck, S. P., & Francis, R. M. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.923.526 · Cited by 51
Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis
McCloskey, E. V., Selby, P. L., de Takats, D., Bernard, J.-C., Davies, M., Robinson, J., Francis, R. M., Adams, J. E., Pande, K. C., Beneton, M. N. C., et al. (2001) · Bone · doi:10.1016/s8756-3282(00)00437-3 · Cited by 51
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1791-y · Cited by 50
Gronholz, M. J. (2008) · PubMed · Cited by 50
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
Saag, K. G., & Geusens, P. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2815 · Cited by 50
Choi, J., Baek, S., Lee, J., & Chang, Y.-I. (2010) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2010.01.031 · Cited by 50
Kishimoto, H., Fukunaga, M., Kushida, K., Shiraki, M., Itabashi, A., Nawata, H., Nakamura, T., Ohta, H., Takaoka, K., & Ohashi, Y. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0706-z · Cited by 50
[Recommendations for the diagnosis and management of osteoporosis].
Tavares, V., Canhão, H. M., Gomes, J. A. M., Simões, E., Romeu, J. C., Coelho, P. C., Santos, R. A., Malcata, A., Araújo, D., Vaz, C., et al. (2007) · PubMed · Cited by 50
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
(2006) · Europe PMC (PubMed Central) · Cited by 50
Bone densitometry and the diagnosis of osteoporosis
Blake, G. M., & Fogelman, I. (2001) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2001.18749 · Cited by 50
Health Technology Assessment in Osteoporosis
Hiligsmann, M., Kanis, J. А., Compston, J. E., Cooper, C. C., Flamion, B., Bergmann, P., Body, J., Boonen, S., Bruyère, O., Devogelaer, J., et al. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9724-8 · Cited by 49
Self-citationShigematsu, T., Muraoka, R., Sugimoto, T., & Nishizawà, Y. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0478-9 · Cited by 49
Tratamiento de la osteoporosis
Nogués, X., & Martínez-Laguna, D. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.10.019 · Cited by 49
II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica
Orjuela, A. M., Rosero, O., Rueda-Plata, P. N., Escobar, F. S., Chalem, M., Reyes, M., Román-Gonzaléz, A., Lozano, A. T., Talero, A. P., Beltz, C. R., et al. (2018) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2018.02.006 · Cited by 49
Tadrous, M., Wong, L., Mamdani, M., Juurlink, D. N., Krahn, M. D., Lévesque, L. E., & Cadarette, S. M. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2576-2 · Cited by 49
Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments
Inderjeeth, C. A., Chan, K., Kwan, K., & Lai, M. M. Y. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0349-1 · Cited by 49
Role of alendronate and risedronate in preventing and treating osteoporosis.
Peters, M. L., Leonard, M., & Licata, A. A. (2001) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.68.11.945 · Cited by 48
Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment
Sebba, A. I. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.03.008 · Cited by 48
Effects of antiresorptive treatment on nonvertebral fracture outcomes
Mackey, D. C., Black, D. M., Bauer, D. C., McCloskey, E. V., Eastell, R., Mesenbrink, P. G., Thompson, J. R., & Cummings, S. R. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.446 · Cited by 48
Self-citationBrown, S. A., & Rosen, C. J. (2003) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00065-8 · Cited by 48
Bisphosphonates pharmacology and use in the treatment of osteoporosis
Diab, D. L., Watts, N. B., & Miller, P. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00074-5 · Cited by 48
Eastell, R., & Riggs, B. L. (2005) · Elsevier eBooks · doi:10.1016/b978-012252687-9/50070-x · Cited by 48
Self-citationOsteoporose em mulheres na pós-menopausa
Radominski, S., Pinto-Neto, A. M., Marinho, R., Costa-Paiva, L., Pereira, F. A., Urbanetz, A. A., Ferrari, A., & Baracat, E. C. (2004) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042004000600006 · Cited by 47
Menatetrenone (Vitamin K2) and Bone Quality in the Treatment of Postmenopausal Osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2006) · Nutrition Reviews · doi:10.1111/j.1753-4887.2006.tb00184.x · Cited by 47
Papapoulos, S. E., & Schimmer, R. C. (2007) · Postgraduate Medical Journal · doi:10.1136/ard.2006.064931 · Cited by 47
Shahnazari, M., Yao, W., Dai, W., Wang, B., Ionova-Martin, S. S., Ritchie, R. O., Heeren, D., Burghardt, A. J., Nicolella, D. P., Kimiecik, M. G., et al. (2010) · Bone · doi:10.1016/j.bone.2009.11.019 · Cited by 46
Kitazaki, S., Mitsuyama, K., MASUDA, J., Harada, K., Yamasaki, H., Kuwaki, K., Takedatsu, H., Sugiyama, G., Tsuruta, O., & Sata, M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03899.x · Cited by 46
Importance of Recent Fracture as Predictor of Imminent Fracture Risk
Schnell, A., Curtis, J. R., & Saag, K. G. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0487-z · Cited by 46
Osteonecrosis de los maxilares: Documento de consenso
Henríquez, M. S., Romero, M. G. D. T., Jv, B. S., Díaz Curiel, M., Díez Pérez, A., Jódar Gimeno, E., Junquera Gutiérrez, L., Del Pino Montes, J., Barrero, M. V., Científico, M. D. C., et al. (2009) · Revista de Osteoporosis y Metabolismo Mineral · Cited by 46
Bone loss and the aromatase inhibitors
Lester, J., & Coleman, R. E. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602691 · Cited by 46
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
Reginster, J., & Rabenda, V. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.415 · Cited by 46
Self-citationClinical role of bisphosphonate therapy
Fogelman, I., & Hampson (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s24783 · Cited by 45
Vescini, F., Attanasio, R., Balestrieri, A., Bandeira, F. A. F., Bonadonna, S., Camozzi, V., Cassibba, S., Cesareo, R., Chiodini, I., Francucci, C. M., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0434-8 · Cited by 45
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.